Guanfacine Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Guanfacine prescriptions, this update provides the current supply status, clinical context, and practical guidance to support continuity of care. While Guanfacine is not currently listed as a formal FDA shortage, localized stock-outs are a real clinical problem — particularly as ADHD prescribing volumes continue to rise and the stimulant shortage drives increased demand for non-stimulants.

Current Supply Status (Early 2026)

As of early 2026, Guanfacine (both IR and ER formulations) is not listed on the FDA Drug Shortages Database or the ASHP Drug Shortage Database. Generic Guanfacine is manufactured by multiple companies, providing supply redundancy that stimulant medications — subject to DEA aggregate production quotas — do not have.

That said, the practical experience of many providers and patients reflects localized availability challenges — particularly for higher-strength ER formulations (3 mg and 4 mg) and in geographic areas with high ADHD prescribing volumes. These are driven by demand-side pressures, not supply-side manufacturing failures.

Why Guanfacine Demand Has Increased

The sustained shortage of stimulant ADHD medications — which began with Adderall in October 2022 and has affected multiple methylphenidate formulations — has increased clinical demand for non-stimulant alternatives including Guanfacine, Atomoxetine, and Clonidine. As stimulant availability has remained inconsistent through 2025 and into 2026, non-stimulant prescriptions have increased substantially.

Additionally, overall ADHD diagnosis rates continue to increase in the U.S., with CDC data indicating over 15.5 million adults with ADHD diagnoses as of 2024. This secular demand growth adds further pressure on non-stimulant supply.

Clinical Implications of Guanfacine Unavailability

When patients cannot fill Guanfacine, prescribers face several clinical challenges:

Rebound hypertension risk: Abrupt discontinuation of Guanfacine can cause rebound hypertension, anxiety, and sympathetic nervous system overshoot. Patients must be counseled never to stop abruptly and to contact you immediately if supply runs out.

ADHD symptom relapse: For pediatric patients using Guanfacine ER for ADHD, even a few days without medication can meaningfully impact academic performance and behavioral functioning, particularly during the school year.

Cardiovascular monitoring interruption: Patients on Guanfacine require ongoing BP and HR monitoring. If they switch medications without provider guidance, cardiovascular parameters may not be re-established appropriately.

Evidence-Based Alternatives to Consider

If Guanfacine is unavailable for an extended period, consider the following evidence-based alternatives, stratified by clinical context:

For ADHD in Children/Adolescents:

Clonidine ER (Kapvay): Most pharmacologically similar; FDA-approved for ADHD ages 6–17. More sedating than Guanfacine due to broader alpha-2 receptor activity (2A, 2B, 2C vs. primarily 2A). Useful when comorbid tics or sleep disturbance are present. Dose conversion: not direct — clonidine starting dose 0.1 mg/day ER, titrated carefully.

Atomoxetine (Strattera generic): FDA-approved for ADHD in children and adults. Selective norepinephrine reuptake inhibitor. Black box warning: increased suicidal ideation in pediatric patients — requires close monitoring. Onset of 2–6 weeks. Not interchangeable in dosing with Guanfacine.

Viloxazine ER (Qelbree): FDA-approved for ADHD in children 6–17 as of 2021. Serotonin norepinephrine modulating agent. Less sedating than alpha-2 agonists. Brand only; may face prior authorization challenges. Can raise levels of CYP1A2 substrates.

For Hypertension (Guanfacine IR):

Guanfacine IR for hypertension has largely been replaced in modern clinical practice by more efficacious agents with better safety profiles. If a patient is reliant on Guanfacine IR for BP management, consider transitioning to a first-line agent (ACE inhibitor, ARB, CCB, or thiazide diuretic) after appropriate cardiovascular assessment. If continuity of a centrally-acting agent is desired, Clonidine IR is a reasonable bridging option.

Dosing Considerations for Switching from Guanfacine to Clonidine ER

There is no established 1:1 dose equivalence between Guanfacine ER and Clonidine ER for ADHD. When switching:

Initiate Clonidine ER at 0.1 mg/day and titrate as per label, regardless of previous Guanfacine dose

Do not switch abruptly — overlap or taper Guanfacine as clinically appropriate

Monitor BP and HR closely during the transition period

Counsel patients and caregivers on increased sedation potential with Clonidine

How medfinder for Providers Can Help

Rather than having your patients or staff spend time calling pharmacies, recommend medfinder for Providers. It contacts pharmacies in your patient's area to identify which ones have their specific Guanfacine strength in stock, and texts results directly to the patient. This reduces the burden on your staff and helps patients get their prescriptions filled faster.

Key Takeaways for Prescribers

No active FDA or ASHP shortage for Guanfacine as of early 2026

Localized stock-outs are real — primarily demand-driven, not supply-chain failures

Counsel all patients on the risk of abrupt discontinuation and have an emergency plan

Clonidine ER is the most pharmacologically similar alternative if a switch is needed

Consider mail-order pharmacy for patients on long-term Guanfacine maintenance